Patient dosing has begun in a Phase III clinical programme investigating GSK’s 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo. Invasive Meningococcal Disease (IMD) is uncommon, with country-specific reported cases ranging from 0.1 to 2.4 cases per 100,000 population in 2017. However, the disease can kill in as few as
“You never change things by fighting the existing reality. To change something, build a new model” Our latest industry analytics report features analysis on the clinical sector within the life sciences industry. Clinical Professionals Group CEO, Yvette Cleland comments: “Covid19 has been a global disruptor in literally every section of society. However, for the future
A highly anticipated COVID-19 vaccine which is being jointly developed by AstraZeneca and Oxford University has produced encouraging results in a phase 1/2 trial. The phase 1/2 results, published in The Lancet demonstrated that the vaccine, AZD1222, produced a robust immune response against the SARS-CoV-2 virus in all participants in the study. The vaccine also proved safe to use,
The American biotech’s COVID-19 vaccine has shown promise in a key early trial by producing antibodies in all the participants tested. The interim analysis of the phase 1 study of the candidate, mRNA-1273, evaluated a two-dose vaccination schedule of the shot given 28 days apart across three dosages – 25, 100, 250 µg – in 45
Regeneron Pharmaceuticals has kickstarted a Phase III trial evaluating its double antibody cocktail for prevention of novel coronavirus infection in uninfected people who have had ‘close exposure’ to a COVID-19 patient in a Phase III trial. The experimental therapy has also advanced into the Phase II/III segment of two adaptive trials assessing its ability to
AstraZeneca will start clinical trials of two antibodies targeting SARS-CoV-2, the virus that causes COVID-19, within the next two months. The two candidates have emerged from a partnership with Vanderbilt University in the US – focusing on up to six coronavirus-targeting neutralising antibodies – which was signed in April. The antibodies have the potential to
Eli Lilly has recently begun dosing patients in the world’s first trial for treatment designed to attack SARS-CoV-2, the virus that causes COVID-19. This investigational treatment, referred to as LY-CoV555, is the first produced as a result of the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Scientists developed
Researchers at Oxford University are working in what has been herald as an unprecedented vaccine development effort to prevent COVID-19, have begun screening healthy volunteers (aged 18-55) for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in
The pharmaceutical company announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor). The drug in combination with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) met its primary endpoint of a statistically significant increase in progression-free survival (PFS) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd). The trial saw the
Now officially classified as a global health threat by the WHO, the Coronavirus epidemic is showing no signs of slowing down. Over 28,000 cases have been confirmed around the world to date, with more than 20 nations reporting cases, some of which also include locals who had not even traveled to China. As a result,
